Aging in blood vessels. Medicinal agents FOR systemic arterial hypertension in the elderly

Ageing Research Reviews

Volumn 18, Issue , 2014, Pages 132-147

  Rubio Ruiz, María Esther ^a   Pérez Torres, Israel ^a   Soto, María Elena ^a   Pastelín, Gustavo ^a   Guarner Lans, Verónica ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Aging; Endothelial cells; Hypertension; Medicinal agents

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARVEDILOL; ENALAPRIL; ENALAPRILAT; HORMONE; NATURAL PRODUCT; NITRIC OXIDE; OLMESARTAN; PROSTAGLANDIN SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AGING; ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERY CALCIFICATION; BLOOD VESSEL; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIFESTYLE MODIFICATION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENESCENCE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; AGE; ANIMAL; ARTERIAL PRESSURE; CELL AGING; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGE FACTORS; AGING; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CELL AGING; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR REMODELING; VASCULAR STIFFNESS;

EID: 84928478540     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.10.001     Document Type: Review

References (179)

1. Argyropoulou A., Aligiannis N., Trougakos I.P., Skaltsounis A.L. Natural compounds with anti-ageing activity. Nat. Prod. Rep. 2013, 30(11):1412-1437.
2. Armentano R.L., Barra J.G., Santana D.B., Pessana F.M., Graf S., Craiem D., Brandani L.M., Baglivo H.P., Sanchez R.A. Smart damping modulation of carotid wall energetics in human hypertension: effects of angiotensin-converting enzyme inhibition. Hypertension 2006, 47(3):384-390.
3. Bachschmid M.M., Schildknecht S., Matsui R., Zee R., Haeussler D.A., Cohen R., Pimental D., Loo B.V. Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease. Ann. Med. 2012, 45(1):17-36.
4. Basaria Sh., Coviello A.D., Travison Th.G., Storer Th.W., Farwell W.R., Jette A.M., Eder R., Tennstedt Sh., Ulloor J., Zhang A., Choong K., Lakshman K.M., Mazer N.A., Miciek R., Krasnoff J., Elmi A., Knapp P.H.E., Brooks B., Appleman E., Aggarwal Sh., Bhasin G., Hede-Brierley L., Bhatia A., Collins L., Nathan LeBrasseur N., Fiore L.D., Bhasin Sh. Adverse events associated with testosterone administration. N. Engl. J. Med. 2010, 363(2):109-122.
5. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., Stoyanovsky V., Antikainen R.L., Nikitin Y., Anderson C., Belhani A., Forette F., Rajkumar C., Thijs L., Banya W., Bulpitt C.J. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008, 358:1887-1898. HYVET Study Group.
6. Belhassen L., Pelle G., Dubois-Rande J.L., Adnot S.J. Improved endothelial function by the thromboxane A2 receptor antagonist S-18886 in patients with coronary artery disease treated with aspirin. Am. Coll. Cardiol. 2003, 41(7):1198-1204.
7. Bender S.B., Newcomer S.C., Harold L.M. Differential vulnerability of skeletal muscle feed arteries to dysfunction in insulin resistance: impact of fiber type and daily activity. Am. J. Physiol. Heart Circ. Physiol. 2011, 300(4):H1434-H1441.
8. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009, 119(3):524-530.
9. Bernhard D., Laufer G. Theaging cardiomyocyte: a mini-review. Gerontology 2008, 54:24-31.
10. Borghi C., Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer. Adher. 2012, 6:449-455.
11. Bramlage P. Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Vasc. Health Risk Manag. 2009, 5(1):213-224.
12. Bramlage P., Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - a review. Cardiovasc. Diabetol. 2009, 8:18.
13. Brandes R.P., Fleming I., Busse R. Endothelial aging. Cardiovasc. Res. 2005, 66:286-294.
14. Briet M., Burns K.D. Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin. Sci. 2012, 123:399-416.
15. Buiyan M.A., Ishiguro M., Hossain M. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci. 2013, 85:136-140.
16. Bulpitt C., Fletcher A., Beckett N., Coope J., Gil-Extremera B., Forette F., Nachev C., Potter J., Sever P., Staessen J., Swift C., Tuomilehto J. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001, 18(3):151-164.
17. Carvajal A., Velasco A., Martin Arias L.H., Maroto M.J. Age-related changes in contractile responses to noradrenaline in isolated blood vessels from rat and rabbit. J. Auton. Pharmacol. 1995, 15(5):321-326.
18. Cassis P., Conti S., Remuzzi G., Benigni A. Angiotensin receptors as determinants of life span. Pflugers Arch. 2010, 459(2):325-332.
19. Cau S.B., Carneiro F.S., Tostes R.C. Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. Front. Physiol. 2012, 3:218.
20. Chan P.C., Hsu R.Y., Liu C.W., Lai C.C., Chen H.C. Adducin-1 is essential for mitotic spindle assembly through its interaction with myosin-X. J. Cell Biol. 2014, 204(1):19-28.
21. Choi H.D., Suh J.H., Lee J.Y., Bae S.K., Kang H.E., Lee M.G., Shin W.G. Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis. Int. J. Clin. Pharmacol. Ther. 2013, 51(9):718-724.
22. Csiszar A., Labisnskyy N., Simith K., Rivera A., Orosz Z., Ungvari Z. Vasculo-protective effects of anti-tumor necrosis factor-alpha treatment in aging. Am. J. Pathol. 2007, 170:388-398.
23. Dai D.F., Rabinovitch P.S., Ungvari Z. Mitochondria and cardiovascular aging. Circ. Res. 2012, 110(8):1109-1124.
24. Dell'Italia L., Ferrario C.M. The never ending story of angiotensin peptides. Beyond angiotensin I and II. Circ. Res. 2013, 112:1086-1087.
25. Díaz-Flores M., Cruz M., Durán-Reyes C., Miranda-Munguía C., Loza-Rodríguez H., Pulido-Casas E., Torres-Ramírez N., Gaja-Rodríguez O., Kumate J., Baiza-Gutman L.A., Hernández-Saavedra D. Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure. Can. J. Physiol. Pharmacol. 2013, 91:855-860.
26. Dini F.L., Ghio S., Klersy C., Rossi A., Simioniuc A., Scelsi L., Genta F.T., Cicoira M., Tavazzi L., Temporelli P.L. Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int. J. Clin. Pract. 2013, 67(7):656-664.
27. Donato A.J., Gano L.B., Eskurza I., Silver A.E., Gates P.E., Jablonski K., Seals D.R. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H425-H432.
28. Donato A.J., Magerko K.A., Lawson B.R., Durrant J.R., Lesniewski L.A., Seals D.R. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J. Physiol. (Lond.) 2011, 589:4545-4554.
29. Egan K., FitzGerald G.A. Eicosanoids and the vascular endothelium. Handb. Exp. Pharmacol. 2006, 176(Pt 1):189-211.
30. El Assar M., Angulo J., Vallejo S., Peiró C., Sánchez-Ferrer C.F., Rodríguez-Mañas L. Mechanisms involved in the aging-induced vascular dysfunction. Front. Physiol. 2012, 3:132.
31. Elgebaly M.M., Kelly A., Harris A.K., Elewa H., Portik-Dobos V., Ketsawatsomkron P., Marrero M., Ergul A. Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: role of endothelin-1. Can. J. Physiol. Pharmacol. 2008, 86(6):358-364.
32. Fagard R.H. Epidemiology of hypertension in the elderly. Am. J. Geriatr. Cardiol. 2002, 11(1):23-28.
33. Farsetti A., Grasselli A., Bacchetti S., Gaetano C., Capogrossi M.C. The telomerase tale in vascular aging: regulation by estrogens and nitric oxide signaling. J. Appl. Physiol. 2009, 106:333-337.
34. Francis S.H., Busch J.L., Corbin J.D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62:525-563.
35. Freitas M.R., Schott C., Corriu C., Sassard J., Stoclet J.C., Ramaroson A. Heterogeneity of endothelium-dependent vasorelaxation in conductrance and resistance arteries from Lyon normotensive and hypertensive rats. J. Hypertens. 2003, 21:1505-1512.
36. Fretheim A., Odgaard-Jensen J., Brørs O., Madsen S., Njølstad I., Norheim O.F., Svilaas A., Kristiansen I.S., Thürmer H., Flottorp S. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med. 2012, 10:33.
37. Frisoli T.M., Schmieder R.E., Grodzicki T., Messerli F.H. Beyond salt: lifestyle modifications and blood pressure. Eur. Heart J. 2011, 32(24):3081-3087.
38. García-Peña C., Thorogood M., Reyes S., Salmeron-Castro J., Duran C. The prevalence and treatment of hypertension in the elderly population of the Mexican Institute of Social Security. Salud Pub. 2001, 43(5):1-6.
39. Giachelli C.M. The emerging role of phosphate in vascular calcification. Kidney Int. 2009, 75:890-897.
40. Goto K., Fujii K., Kansui Y., lida M. Changes in endothelium derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with reninangiotensin system inhibitors. Clin. Exp. Pharmacol. Physiol. 2004, 31:650-655.
41. Goto K., Fujii K., Onaka U., Abe I., Fujishima M. Angiotensin converting enzyme inhibitor prevents age-related endothelial dysfunction. Hypertension 2000, 36:581-587.
42. Guarner-Lans V., Rubio-Ruiz M.E. Aging, metabolic syndrome and the heart. Aging Dis. 2012, 3(3):269-279.
43. Gunasekaran U., Gannon M. Type 2 diabetes and the aging pancreatic beta cell. Aging (Albany, N. Y.) 2011, 3(6):565-575.
44. Hausberg M., Hoffman R.P., Somers V.K., Sinkey C.A., Mark A.L., Anderson E.A. Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension 1997, 29(3):700-705.
45. Hayashi T., Matsui-Hirai H., Miyazaki-Akita A., Fukatsu A., Funami J., Ding Q.F., Kamalanathan S., Hattori Y., Ignarro L.J., Iguchi A. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17018-17023.
46. Hennan J.K., Huang J., Barrett T.D., Driscoll E.M., Willens D.E., Park A.M., Crofford L.J., Lucchesi B.R. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001, 104:820-825.
47. Henriksen E.J. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293(3):R974-R980.
48. Hinschen A.K., Rose'Meyer R.B., Headrick J.P. Age-related changes in adenosine-mediated relaxation of coronary and aortic smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 2001, 280(5):H2380-H2389.
49. Hintzpeter J., Stapelfeld C., Loerz C., Martin H.J., Maser E. Green tea and one of its constituents, epigallocatechine-3-gallate, are potent inhibitors of human 11b-hydroxysteroid dehydrogenase type 1. PLoS ONE 2014, 9(1):e84468.
50. Hlavačková L., Janegová A., Uličná O., Janega P., Cerná A., Babál P. Spice up the hypertension diet - curcumin and piperine prevent remodeling of aorta in experimental l-NAME induced hypertension. Nutr. Metab. 2011, 8:72.
51. Houston M. The role of nutrition and nutraceutical supplements in the treatment of hypertension. World J. Cardiol. 2014, 6(2):38-66.
52. Idris Khodja N., Chataigneau T., Auger C., Schini-Kerth V.B. Grape-derived polyphenols improve aging-related endothelial dysfunction in rat mesenteric artery: role of oxidative stress and the angiotensin system. PLoS ONE 2012, 7:e32039.
53. Jacob M.P. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed. Pharmacother. 2003, 57(5-6):195-202.
54. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens. Res. 2008, 31:2115-2127. JATOS Study Group.
55. Jung S.B., Kim C.S., Naqvi A., Yamamori T., Mattagajasingh I., Hoffman T.A., Cole M.P., Kumar A., Dericco J.S., Jeon B.H., Irani K. Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ. Res. 2010, 107:877-887.
56. Kaiser E.A., Lotze U., Schäfer H.H. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?. Clin. Interv. Aging 2014, 9:459-475.
57. Kalyani R.R., Egan J.M. Diabetes and altered glucose metabolism with aging. Endocrinol. Metab. Clin. North Am. 2013, 42(2):333-347.
58. Kansui Y., Fujii K., Goto K., Abe I., lida M. Angiotensin II receptor antagonist improves agerelated endothelial dysfunction. J. Hypertens. 2002, 20:439-446.
59. Kereiakes D.J., Chrysant S.G., Izzo J.L., Littlejohn T., Melino M., Lee J., Fernandez V., Heyrman R. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc. Diabetol. 2012, 11:134.
60. Khatchadourian Z.D., Moreno-Hay I., de Leeuw R. Nonsteroidal anti-inflammatory drugs and antihypertensives: how do they relate?. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2014, 117(6):697-703.
61. Kotsis V., Stabouli S., Karafillis I., Nilsson P. Early vascular aging and the role of central blood pressure. J. Hypertens. 2011, 29:1847-1853.
62. Krousel-Wood M.A., Muntner P., Islam T., Morisky D.E., Webber L.S. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med. Clin. Am. 2009, 93(3):753-769.
63. Küng C.F., Lüscher T.F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995, 25:194-200.
64. Lähteenvuo J., Rosenzweig A. Effects of aging on angiogenesis. Circ. Res. 2012, 110(9):1252-1264.
65. Lajemi M., Gautier S., Benetos A. Rigidity of large arteries and cardiovascular risk epidemiological aspects and genetic determinants. Pathol. Biol. (Paris) 1999, 47(6):614-622.
66. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
67. Lassegue B., Griendling K.K. NADPH oxidase: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 2010, 30:653-661.
68. Laurent S. Defining vascular aging and cardiovascular risk. J. Hypertens. 2012, 30(Suppl.):S3-S8.
69. Laurent S., Alivon M., Beaussier H., Boutouyrie P. Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. Ann. Med. 2012, 44(Suppl. 1):S93-S97.
70. Laurent S., Mousseaux E., Boutouyrie P. Arterial stiffness as an imaging biomarker. Are all pathways equal?. Hypertension 2013, 62:10-12.
71. Laurent S., Schlaich M., Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012, 380(9841):591-600.
72. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
73. Lee D.H., Lee J.U., Kang D.G., Paek Y.W., Chung D.J., Chung M.Y. Increased vascular endothelin-1 gene expression with unaltered nitric oxide synthase levels in fructose-induced hypertensive rats. Metabolism. 2001, 50(1):74-78.
74. Lin C.S., Liu X., Tu R., Chow S., Lue T.F. Age-related decrease of protein kinase G activation in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2001, 287(1):244-248.
75. Lipsitz L.A. A 91-year-old woman with difficult-to-control hypertension: a clinical review. JAMA 2013, 310(12):1274-1280.
76. Long D.A., Newaz M.A., Prabhakar S.S., Price K.L., Troung L.D., Feng L., Mu W., Oyekan A.O., Johnson R.J. Loss of nitric oxide and endothelial-derived hyperpolarizing factor-mediated responses in aging. Kidney Int. 2005, 68:2154-2163.
77. Lopes R.A.M., Neves K.B., Carneiro F.S., Tostes R.C. Testosterone and vascular function in aging. Front. Physiol. 2012, 3:89.
78. Loscalzo J. The identification of nitric oxide as endothelium-derived relaxing factor. Circ. Res. 2013, 113(2):100-103.
79. Lu M.H., Wu G.C., Chao C.F. Comparison of endothelin binding sites in cultured aortic smooth muscle cells from spontaneously hypertensive and normotensive rats. Jpn. Circ. J. 1998, 62(7):532-536.
80. Lundberg M.S., Crow M.T. Age-related changes in the signaling and function of vascular smooth muscle cells. Exp. Gerontol. 1999, 34(4):549-557.
81. Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013, 31(7):1281-1357. Task Force Members.
82. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE Randomized trial. Ann. Intern. Med. 2001, 134:629-636.
83. Matz R.L., Alvarez de Sotomayor M., Schott C., Andriantsitohaina R. Preservation of vascular contraction during ageing: dual effect on calcium handling and sensitization. Br. J. Pharmacol. 2003, 138:745-750.
84. Meredith P. Comparative ARB pharmacology. Br. J. Cardiol. 2010, 17:s3-s5.
85. Minamino T., Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ. Res. 2007, 100:15-26.
86. Minamino T., Miyauchi H., Yoshida T., Tateno K., Komuro I. The role of vascular cell senescente in atherosclerosis: antisenescence as a novel therapeutic strategy for vascular aging. Curr. Vasc. Pharmacol. 2004, 2:141-148.
87. Montagnani M., Vulpis V., Nazzaro P., Potenza M.A., Rinaldi R., Nacci C., De Salvia M.A., Siro-Brigiani G., Pirrelli A., Mitolo-Chieppa D.J. Endothelin-1-receptor-mediated responses in resistance vessels of young and adult spontaneously hypertensive rats. Hypertension 2000, 18(7):893-900.
88. Moon S.K., Thompson L.J., Madamanchi N., Ballinger S., Papaconstantinou Horaist C., Runge M.S., Patterson C. Aging, oxidative responses, and proliferative capacity in cultured mouse aortic smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2001, 280(6):H2779-H2788.
89. Morgenstern N., Byyny R.L. Epidemiology of hypertension in the elderly. Drugs Aging 1992, 2(3):222-242.
90. Mukai Y., Shimiokawa H., Higashi M., Morikawa K., Matoba T., Hiroki J., Kunihiro I., Talikder H.M., Takeshita A. Inhibition of rennin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1445-1450.
91. Mukherjee P.K., Chawla A., Loayza M.S., Bazan N.G. Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77(5-6):233-238.
92. Musini V.M., Rezapour P., Wright J.M., Bassett K., Jauca C.D. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst. Rev. 2012, 8:CD003825.
93. Nakamura T., Fujiwara N., Kawagoe Y., Sugaya T., Ueda Y., Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur. J. Clin. Invest. 2010, 40(9):790-796.
94. Nava P., Guarner V., Posadas R., Perez I., Baños G. Insulin-induced endothelin release and vasoactivity in hypertriglyceridemic and hypertensive rats. Am. J. Physiol. 1999, 277(Heart. Circ. Physiol. (46)):H399-H404.
95. Nilsson P.M. Hemodynamic aging as the consequence of structural changes associated with early vascular aging (EVA). Aging Dis. 2014, 5(2):109-113.
96. Nilsson P.M., Boutouyrie P., Cunha P., Kotsis V., Narkiewicz K., Parati G., Rietzschel E., Scuteri A., Laurent S. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J. Hypertens. 2013, 8:1517-1526.
97. Nilsson P.M., Boutouyrie P., Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension 2009, 54:3-10.
98. Nilsson P.M., Lurbe E., Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. J. Hypertens. 2008, 26:1049-1057.
99. Nishiyama A., Matsusaka T., Miyata T. Angiotensin II type 1A receptor deficiency and longevity. Nephrol. Dial. Transplant. 2009, 24(11):3280-3281.
100. Novella S., Dantas A.P., Segarra G., Medina P., Hermenegildo C. Vascular aging in women: is estrogen the fountain of youth?. Front. Physiol. 2012, 3:165.
101. Nyberg M., Blackwell J.R., Damsgaard R., Jones A.M., Hellsten Y., Mortensen S.P. Lifelong physical activity prevents an age-related reduction in arterial and skeletal muscle nitric oxide bioavailability in humans. J. Physiol. 2012, 590(Pt 21):5361-5370.
102. Opiyo N., Shepperd S., Musila N., English M., Fretheim A. The Child Health Evidence Week and GRADE grid may aid transparency in the deliberative process of guideline development. J. Clin. Epidemiol. 2012, 65(9):962-969.
103. Ota H., Eto M., Kano M.R., Ogawa S., Lijima K., Akishita M., Ouchi Y. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1634-1639.
104. Palatini P., Casiglia E., Gasowski J., Głuszek J., Jankowski P., Narkiewicz K., Saladini F., Stolarz-Skrzypek K., Tikhonoff V., Van Bortel L., Wojciechowska W., Kawecka-Jaszcz K. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc. Health Risk Manag. 2011, 7:725-739.
105. Pang C.Y., Ma Y.S., Wei Y.U. MtDNA mutations, functional decline and turnover of mitochondria in aging. Front. Biosci. 2008, 13:3661-3675.
106. Pérez-Torres I., Ruiz-Ramírez A., Baños G., El-Hafidi M. Hibiscus sabdariffa Linnaeus (Malvaceae), curcumin and resveratrol as alternative medicinal agents against metabolic syndrome. Cardiovasc. Hematol. Agents Med. Chem. 2013, 11(1):25-37.
107. Peters R., Beckett N., Fagard R., Thijs L., Wang J.G., Forette F., Pereira L., Fletcher A., Bulpitt C. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial - HYVET. J. Hypertens. 2013, 31(9):1868-1875.
108. Pignone M., Williams C.D. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat. Rev. Endocrinol. 2010, 6(11):619-628.
109. Potente M., Dimmeler S. NO targents SIRT1: a novel signaling network in endothelial senescence. Arterioscler. Thromb. Vasc. Biol. 2008, 28:577-1579.
110. Preobrazhenskiĭ D.V., Nekrasova N.I., Khoseva E.N., Arystanova A., Talyzina I.V., Pataraia S.A. Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension. Kardiologiia 2011, 51(4):67-73.
111. Priebe H.J. Influence of beta-blockers on the outcome of at risk patients. Minerva Anestesiol. 2009, 75(5):319-323.
112. Pruijm M.T., Maillard M.P., Burnier M. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc. Health Risk Manag. 2008, 4(6):1159-1166.
113. Qabazard B., Ahmed S., Li L., Arlt V.M., Moore P.K., Stürzenbaum S.R. C. elegans aging is modulated by hydrogen sulfide and the sulfhydrylase/cysteine synthase cysl-2. PLoS ONE 2013, 8(11):e80135.
114. Qian H., Luo N., Chi Y. Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders. J. Aging Res. 2012, 2012:121390.
115. Raheja P., Price A., Wang Z., Arbique D., Adams-Huet B., Auchus R.J., Vongpatanasin W. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012, 60(2):319-325.
116. Rende P., Paletta L., Gallelli G., Raffaele G., Natale V. Retrospective evaluation of adverse drug reactions induced by antihypertensive treatment. J. Pharmacol. Pharmacother. 2013, 4(Suppl. 1):S47-S50.
117. Rosendorf C. Hypertension. The AHA Guidelines and Scientific Statements Handbook 2009, 196-213. Wiley & Blackwell, West Sussex, UK. V. Fuster (Ed.).
118. Rubio-Ruiz M.E., El Hafidi M., Pérez-Torres I., Baños G., Guarner V. Medicinal agents and metabolic syndrome. Curr. Med. Chem. 2013, 20(21):2626-2640.
119. Rubio-Ruiz M.E., Baños G., Díaz E., Guarner V. Effect of age on insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Exp. Gerontol. 2006, 41(3):282-288.
120. Rubio-Ruiz M.E., Guarner-Lans V. Inflammation and the use of anti-inflammatory agents in signs and cardiovascular consequences of metabolic syndrome. Handbook on Metabolic syndrome. Classification, Risk Factors and Health Impact 2012, 169-188. Nova Biomedical, New York. C.M. Lopez-Grcia, P.A. Perez-González (Eds.).
121. Ruiz-Torres A., Lozano R., Melón J., Carraro R. Age-dependent decline of in vitro migration (basal and stimulated by IGF-1 or insulin) of human vascular smooth muscle cells. J. Gerontol. A. Biol. Sci. Med. Sci. 2003, 58(12):B1074-B1077.
122. Santhanam L., Cristianson D.W., Nyhan D., Berkowitz D.E. Arginase and vascular aging. J. Appl. Physiol. 2008, 105:1632-1642.
123. Santos M.S., Joles J.A. Early determinants of cardiovascular disease. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26(5):581-597.
124. Sasamura H., Shimizu-Hirota R., Saruta T. Extracellular matrix remodeling in hypertension. Curr. Hypertens. Rev. 2005, 1:51-60.
125. Savoia C., Burger D., Nishigaki N., Montezano A., Touyz R.M. Angiotensin II and the vascular phenotype in hypertension. Expert Rev. Mol. Med. 2011, 13:e11.
126. Schiattarella G.G., Perrino C., Magliulo F., Carbone A., Bruno A.G., De Paulis M., Sorropago A., Corrado R.V., Bottino R., Menafra G., Abete R., Toscano E., Giugliano G., Trimarco B., Esposito G. Physical activity in the prevention of peripheral artery disease in the elderly. Front. Physiol. 2014, 5:12.
127. Schrage W.G., Eisenach J.H., Joyner M.J. Ageing reduces nitric-oxide- and prostaglandin mediated vasodilatation in exercising humans. J. Physiol. (Lond.) 2007, 579:227-236.
128. Schulman I.H., Zhou M.S., Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J. Hypertens. Suppl. 2006, 24(1):S45-S50.
129. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., Boger R.H. Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects. Eur. J. Clin. Invest. 2005, 35:622-626.
130. Scuteri A., Cunha P.G., Rosei E.A., Badariere J., Bekaert S., Cockcroft J.R., Cotter J., Cucca F., De Buyzere M.L., De Meyer T., Ferrucci L., Franco O., Gale N., Gillebert T.C., Hofman A., Langlois M., Laucevicius A., Laurent S., Mattace-Raso F.U., Morrell C.H., Muiesan M.L., Munnery M.M., Navickas R., Oliveira P., Orru' M., Pilia M.G., Rietzschel E.R., Ryliskyte L., Salvetti M., Schlessinger D., Sousa N., Stefanadis C., Strait J., Van daele C., Villa I., Vlachopoulos C., Witteman J., Xaplanteris P., Nilsson P., Lakatta E.G. Arterial stiffness and influences of the metabolic syndrome: a cross-countries study. Atherosclerosis 2014, 233(2):654-660. MARE (Metabolic syndrome, Arteries REsearch) Consortium.
131. Seals D.R., Jablonski K.L., Donato A.J. Aging and vascular endothelial function in humans. Clin. Sci. (Lond.) 2011, 120(9):357-375.
132. Sell D.R., Monnier V.M. Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology 2012, 58(3):227-237.
133. Semba R.D., Nicklett E.J., Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype?. J. Gerontol. A. Biol. Sci. Med. Sci. 2010, 65:963-975.
134. Seo B., Lüscher T. ETA and ETB receptors mediate contraction to ET-1 in renal artery of aging SHR. Hypertension 1995, 25:501-506.
135. Shalimova A. Correction of endothelial dysfunction in patients with essential hypertension and type 2 diabetes. Georg. Med. News 2014, 229:33-40.
136. Shi L., Liu X., Li N., Liu B., Liu Y. Aging decreases the contribution of MaxiK channel in regulating vascular tone in mesenteric artery by unparallel downregulation of α- and β1-subunit expression. Mech. Ageing Dev. 2013, 134(9):416-425.
137. Shimoda L.A., Laurie S.S. Vascular remodeling in pulmonary hypertension. J. Mol. Med. (Berl.) 2013, 91(3):297-309.
138. Sica D.A., Carter B., Cushman W., Hamm L. Thiazide and loop diuretics. J. Clin. Hypertens. (Greenwich) 2011, 13(9):639-643.
139. Staessen J.A., Thijs L., Fagard R., O'Brien E.T., Clement D., de Leeuw P.W., Mancia G., Nachev C., Palatini P., Parati G., Tuomilehto J., Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999, 282:539-546.
140. Steichen O., Plouin P.F. Current management of arterial hypertension. Rev. Med. Interne 2014, 35(4):235-242.
141. Strokes G.S. Management of hypertension in the elderly patient. Clin. Interv. Aging 2009, 4:379-389.
142. Sun D., Huang A., Yan E.H., Wu Z., Yan C., Kaminski P.M., Oury T.D., Wolin M.S., Kaley G. Reduced release of nitric oxide to shear stress in mesenteric arteries of aged rats. Am. J. Physiol. Heart Circ. Physiol. 2004, 286(6):H2249-H2256.
143. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 2007, 6:917-935.
144. Tabernero A., Vila E. Effect of age on noradrenaline responses in rat tail artery and aorta: role of endothelium. J. Auton. Pharmacol. 1995, 15(5):327-333.
145. Thijs L., Fagard R., Lijnen P., Staessen J., Van Hoof R., Amery A. A meta-analysis of outcome trials in elderly hypertensives. J. Hypertens. 1992, 10(10):1103-1109.
146. Thijssen D.H., Rongen G.A., van Dijk A., Smits P., Hopman M.T. Enhanced endothelin-1-mediated leg vascular tone in healthy older subjects. J. Appl. Physiol. 2007, 103:852-857.
147. Thijssen D.H.J., Rongen G.A., Smits P., Hopman M.T.E. Physical (in)activity and endothelium-derived constricting factors: overlooked adaptations. J. Physiol. 2008, 586:319-324.
148. Ting C.T., Chen C.H., Chang M.S., Yin F.C. Short and long term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. Hypertension 1995, 26:524-530.
149. Ting C.T., Yang T.M., Chen J.W., Chang M.S., Yin F.C. Arterial hemodynamic in human hypertension. Effects of angiotensin converting enzyme inhibition. Hypertension 1993, 22:839-846.
150. Torregrossa A.C., Aranke M., Bryan N.S. Nitric oxide and geriatrics: implications in diagnostics and treatment of the elderly. J. Geriatr. Cardiol. 2011, 8(4):230-242.
151. Touyz R.M. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr. Opin. Nephrol. Hypertens. 2005, 14:125-131.
152. Turnbull F., Woodward M., Neal B., Barzi F., Ninomiya T., Chalmers J., Perkovic V., Li N., MacMahon S. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur. Heart J. 2008, 29(21):2669-2680. Blood Pressure Lowering Treatment Trialists' Collaboration.
153. Tzourio C.H., Laurent S., Debette S. Is hypertension associated with an accelerated aging of the brain?. Hypertension 2014, 63:894-903.
154. Uddin M., Yang H., Shi M., Polley-Mandal M., Guo Z. Elevation of oxidative stress in the aorta of genetically hypertensive mice. Mech. Ageing Dev. 2003, 124(7):811-817.
155. Ungvari Z., Kaley G., De Cabo R., Sonntag W.E., Csiszar A. Mechanisms of vascular aging: new perspectives. J. Gerontol. A. Biol. Sci. Med. Sci. 2010, 65:1028-1041.
156. Valentina O., Puntmann P.C., Taylor M.M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging. Gerontology 2011, 57:295-300.
157. Van Bortel L.M., Laurent S., Boutouyrie P., Chowienczyk P., Cruickshank J.K., De Backer T. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J. Hypertens. 2012, 30:445-448. Artery Society, European Society of Hypertension Working Group on Vascular Structure, Function, European Network for Non-invasive Investigation of Large Arteries.
158. van der Loo B., Labugger R., Aebischer C.P., Skepper J.N., Bachschmid M., Spitzer V., Kilo J., Altwegg L., Ullrich V., Luscher T.F. Cardiovascular aging is associated with vitamin E increase. Circulation 2002, 105(14):1635-1638.
159. van der Loo B., Labugger R., Skepper J.N., Bachschmid M., Kilo J., Powell J.M., Palacios-Callender M., Erusalimsky J.D., Quaschning T., Malinski T., Gygi D., Ullrich V., Lüscher T.F. Enhanced peroxynitrite formation is associated with vascular aging. J. Exp. Med. 2000, 192:1731-1743.
160. Van Guilder G.P., Westby C.M., Greiner J.J., Stauffer B.L., DeSouza C.A. Endothelin-1 vasoconstrictor tone increases with age in healthy men but can be reduced by regular aerobic exercise. Hypertension 2007, 50:403-409.
161. Vasa M., Breitschopf K., Zeiher A.M., Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ. Res. 2000, 87:540-542.
162. Verma P., Gauttam V., Kalia A.N. Comparative pharmacognosy of Pashanbhed. J. Ayurveda Integr. Med. 2014, 5:104-108.
163. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br. J. Pharmacol. 2009, 157:527-536.
164. Vessières E., Guihot A.L., Toutain B., Maquigneau M., Fassot C., Loufrani L., Henrion D. COX-2-derived prostanoids and oxidative stress additionally reduce endothelium-mediated relaxation in old type 2 diabetic rats. PLoS ONE 2013, 8(7):e68217.
165. Vita J.A., Keaney J.F. Exercise-toning up the endothelium. N. Engl. J. Med. 2000, 342:503-505.
166. Volpe M., Tocci G. Olmesartan in the treatment of hypertension in elderly patients: a review of the primary evidence. Drugs Aging 2013, 30(12):987-998.
167. Wei Y., Schober A., Weber C. Pathogenic arterial remodeling: the good and bad of microRNAs. Am. J. Physiol. Heart Circ. Physiol. 2013, 304(8):H1050-H1059.
168. Weber M.A., Schiffrin E.L., White W.B., Mann S., Lindholm L.H., Kenerson J.G., Flack J.M., Carter B.L., Materson B.J., Ram C.V., Cohen D.L., Cadet J.C., Jean-Charles R.R., Taler S., Kountz D., Townsend R.R., Chalmers J., Ramirez A.J., Bakris G.L., Wang J., Schutte A.E., Bisognano J.D., Touyz R.M., Sica D., Harrap S.B. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J. Clin. Hypertens. (Greenwich) 2014, 16(1):14-26.
169. Williamson K., Stringer S.E., Alexander M.Y. Endothelial progenitor cells enter the aging arena. Front. Physiol. 2012, 3:30.
170. Wray D.W., Nishiyama S.K., Harris R.A., Zhao J., McDaniel J., Fjeldstad A.S., Witman M.A., Ives S.J., Barrett-O'Keefe Z., Richardson R.S. Acute reversal of endothelial dysfunction in the elderly after antioxidant consumption. Hypertension 2012, 59(4):818-824.
171. Yamagishi S., Matsui T. Nitric oxide, a janus-faced therapeutic garget for diabetic microangiopathy - friend of foe?. Pharmacol. Res. 2011, 64:187-194.
172. Yang X.P., Pei Z.H., Ren J. Making up or breaking up: the tortuous role of platelet-derived growth factor in vascular ageing. Clin. Exp. Pharmacol. Physiol. 2009, 36(8):739-747.
173. Yang X.P., Touyz R.M., Nguyen P.V., Deng L.Y., Li J.S., Schiffrin E.L. Endothelin-1 and vasopressin signaling in blood vessels of young SHR in comparison to adult SHR. Hypertens. Res. 1996, 19(2):121-132.
174. Yoon H.E., Choi B.S. The renin-angiotensin system and aging in the kidney. Korean J. Intern. Med. 2014, 29(3):291-295.
175. Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal. J. Hypertens. 2009, 27:923-934.
176. Zhang L.N., Liu P.P., Wang L., Yuan F., Xu L., Xin Y., Fei L.J., Zhong Q.L., Huang Y., Xu L., Hao L.M., Qiu X.J., Le Y., Ye M., Duan S. Lower ADD1 gene promoter DNA methylation increases the risk of essential hypertension. PLoS ONE 2013, 8(5):e63455.
177. Zhang Y., Tang Z.H., Ren Z., Qu S.L., Liu M.L., Liu M.S., Jiang Z.S. Hydrogen sulfide, the next potent preventive and therapeutic agent in aging and age-associated diseases. Mol. Cell. Biol. 2013, 33(6):1104-1113.
178. Zhang Y., Zhang X., Liu L., Zanchetti A. Is a systolic blood pressure target 140mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur. Heart J. 2011, 32:1500-1508.
179. Zu Y., Liu L., Lee M.Y., Xu C., Liang Y., Man R.Y., Vanhoutte P.M., Wang Y. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ. Res. 2010, 106(8):1384-1393.